GVK Biosciences and Crelux set up fragment-based discovery platform
This article was originally published in Scrip
Executive Summary
GVK Biosciences, an Indian contract research organisation, and Crelux of Germany have set up a fragment-based drug discovery platform to help develop viable lead molecules. Crelux is expected to use its capabilities in multi-faceted structural studies including X-ray elucidation of fragment or lead target complexes, while GVK will handle all discovery chemistry and biology work including in silico, in vitro and in vivo studies and activities necessary to ensure preclinical candidate nomination.